IS39 CP6108 [1]

Transcription

1 :28: (human papillomavirus, HPV) DNA IS39 CP6108 ( ) [1] , ,000 [2] ( low-grade squamous intraepithelial lesion, LSIL high-grade squamous (03) DOI: /ICJ _28(3).0002

2 113 intraepithelial lesion, HSIL) (invasive cancer) DNA [3] (persistent infection) E6/E7 P53 prb (retinoblastoma) P53 prb [4] 40,000 [2] ( ) 5 38 [5] 1984~ ~ [6] ( ) 3~230 [7] 2.6 [8] HPV 9 26 [9] [10] 2004~ , , ITT (intention-to-treat) 2,032 2, ( ) % (95% 40.8~73.8) HPV % (95% 45.8~78.6) ( 6 1 ) 107 6

3 % (95% 36~57.6) PPE (per-protocol efficacy) ( ) 2,805 1,397 1, % (95% 69.2~98.1) 85.6% (97.5% 73.4~92.9) 602 [11] HPV (anal intraepithelial neoplasia, AIN II III) ITT 54.2% (95% 25.7~67.2) PPE 74.9% (95% 39.6~93.3) ITT ITT 59.4% (95% 43.0~71.4) PPE 94.9% (95% 80.4~99.4) 27.4% % (27~45 ) [12] ~26 [13] 59% ( ) HPV % 6% [14] ~14 (84%) 90% [15] Wilkin [16] (AIDS Malignancy Consortium protocol 052) AIN II III 44 HPV-6 98% HPV-11 99% HPV % HPV-18 95%

4 115 CD4 + T HIV ACTG A5298 [17] 575 (80% ) 27 ( 47 ) 130 Swedish [18] 202 AIN II III (88 ) (114 ) AIN II III (95% 5.3~17.8) AIN II III (95% 10.9~21.0) 2014 [19] 14,215 16~26 CIN (cervical intraepithelial neoplasia) HPV % (95% 80.9~99.8) HPV ~26 1, ,101 [20] 99.5% Advisory Committee on Immunization Practices (ACIP) ~26 9 [21] ACIP 15 (0, 6~12 ) JCVI 2015 [22] 40 [23]

5 Bonnez W, Reichman RC: Chapter 141 Papillomaviruses. In:Mandell, Douglas, and Bennett s Principles and Practice of Infectious Diseases. Philadelphia: Elsevier 2005: World Health Organization (2018, Feb 3). International agency for research on cancer. Globocan, Available Default.aspx. 3. Palefsky JM: Human papillomavirus-related disease in men: not just a women s issue: J Adolesc Health 2010;46: Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110: Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92: D Souza G, Wiley DJ, Li X, et al: Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008;48: Chaturvedi AK: Epidemiology and clinical aspects of HPV in head and neck cancers: Head Neck Pathol 2012;6: Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, : Ann Intern Med 2008;148: Lauri E, Markowitz LE, Dunne EF, et al: Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2014;63: Giuliano AR, Palefsky JM, Goldstone S, et al: Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364: Palefsky JM, Giuliano AR, Goldstone S, et al: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365: Giuliano AR, Isaacs-Soriano K, Torres BN, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)-the MAM Study. Vaccine 2015;33: Chow EP, Read TR, Wigan R, et al: Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Dis 2015;91: Chow EPF, Machalek DA, Tabrizi SN, et al: Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Inf Dis 2017;11: Zhang L, Regan DG, Ong JJ, et al: Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is costeffective. Vaccine 2017;35: Wilkin T, Lee JY, Lensing SY, et al: Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV1-Infected Men. J Infect Dis 2010;202: Us National Library of Medicine (2018, Feb 3). Vaccine therapy in preventing Human

6 117 papillomavirus infection in young HIVpositive male patients who have sex with males. In: ClinicalTrials.gov [Internet]. Available NCT ?term=NCT NLM Identifier: NCT Swedish KA, Factor SH, Goldstone SE: Prevention of recurrent highgrade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012;54: Joura EA, Giuliano AR, Iversen OE, et al: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372: Castellsagué X, Giuliano AR, Goldstone S, et al: Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine 2015;33: Petrosky E, Bocchini JA Jr, Hariri S, et al: Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR 2015;64: Joint Committee on Vaccination and Immunisation (JCVI 2018, Feb 3). Interim position statement on HPV vaccination of men who have sex with men (MSM). Available https: // government/uploads/system/uploads/attachment_ data/file/373531/jcvi_interim_statement_hpv_ vacc.pdf 23. European AIDS Clinical Society (2017, Nov 17). EACS guidelines V9.0. Available pdf 107 6

7 118 HPV Vaccines: Not a Privilege for Girls Shu-Hsing Cheng Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan Girls aged between 9 and 26 years are recommended to receive human papilloma virus (HPV) vaccinations in Taiwan, but boys are not. Meanwhile, both girls and boys are suggested to receive HPV vaccinations in Australia, the United States, and some European countries. In 2017, the European AIDS Clinical Society guidelines suggested that men who have sex with men, with human immunodeficiency virus infections, and who are aged less than 40 years should receive HPV vaccines. This review article discusses the epidemiology of HPV infections and HPV-related genital lesions, cutting-edge clinical trials, and the proposal of a vaccination strategy for target populations in Taiwan. Key words: HPV vaccines